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CASE REPORT | LIVER
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Abstract
Severe cholestasis with anabolic androgenic steroids is well-known to cause acute liver injury. Treatment is 
usually supportive after withdrawal of the offending agent. Acute kidney injury (AKI) frequently occurs in acute 
liver injury and may complicate management and prognosis. We highlight the use of plasmapheresis resulting 
in rapid improvement in cholestatic jaundice with resolution of AKI. Plasmapheresis should be considered in 
special cases in which there is progressive clinical decline despite supportive care.
Introduction
It has been reported that greater than 40% of the U.S. population consumes herbal and dietary supplements 
(HDS).1 In the past decade alone, a 3-fold rise in liver-related injury attributable to HDS has been reported.2 HDS 
containing anabolic androgen steroids (AAS) may cause severe cholestatic jaundice, debilitating pruritus, and 
persistent acute kidney injury (AKI) from suspected bile acid nephropathy. The cholestasis from AAS is usually 
bland, may last for several months, and eventually resolves once the offending agent is removed, without the 
need for liver transplantation in the majority of cases. However, deaths have been reported due to secondary 
effects of malnutrition, renal failure, and infection.3 
Case Report
A 31-year-old man was admitted to the hospital for mild confusion, severe pruritus, jaundice, and AKI. Sixteen 
weeks prior to presentation, he started an HDS regimen for weight loss and muscle building. On average, he 
consumed 22 capsules per day from 8 different HDS bottles containing at least 80 ingredients, including a 
cumulative daily dose (104 mg) of anabolic steroids 4-chloro-17αmethyl-andro-4-ene-3,17β-diol (50 mg) and 
2α,3αepithio-17αmethyl-51-androstan-17β-ol (54 mg). After reporting fatigue and change in skin color to his 
local gastroenterologist, HDS was stopped due to suspected drug-induced liver injury.
He was hospitalized for severe jaundice with total bilirubin of 53 mg/dL. Viral, autoimmune, and inherited causes 
of liver disease were ruled out. Magnetic resonance cholangiopancreatography ruled out biliary tract pathology 
or obstruction. Liver biopsy showed significant cholestasis and mild intraparenchymal neutrophilic infiltrate in 
hepatocytes surrounding the central veins with no significant necrosis, bile duct injury, or steatosis (Figure 1). 
Supportive care was provided with intravenous (IV) fluids for pre-renal azotemia, while hydroxyzine, cholestyr-
amine, ursodiol, sertraline, naloxone, and topical emollients were sequentially used for pruritus, with minimal 
relief. He was started on IV solumedrol 30 mg daily with no improvement in jaundice after 11 days. Over 2 sub-
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sequent hospitalizations he continued to have AKI (creatinine 
2 mg/dL), persistent jaundice (total bilirubin 46.5 mg/dL), 
and uncontrolled pruritus. He lost 100 lbs, developed severe 
insomnia due to pruritus, reported hallucinations, and was 
re-admitted for concerns of encephalopathy and liver failure. 
Exam revealed a chronically ill-appearing man with a flat af-
fect, scleral icterus, and pronounced jaundice. He was well-
oriented to questions but displayed asterixis. He had no ten-
der hepatomegaly, but had extensive excoriations on his torso 
and extremities induced by pruritus. He had temporal wasting 
and loss of adipose tissue in his arms and abdomen. Labora-
tory results during his third hospital admission included an 
albumin level of 4.7 mg/dL and a prothrombin time of 9.5 s.
Bile acid nephropathy was suspected due to prolonged ex-
posure to significantly high levels of bile acids at 135 mmol/L 
(normal <10 mmol/L). Bile acid nephropathy was supported 
by renal biopsy showing prominent yellow staining of the epi-
thelial lining and the presence of intraluminal bile casts (Fig-
ure 2). On hospital day 7, his creatinine was 2.3 mg/dL, BUN 
48 mg/dL, and total bilirubin 44.6 mg/dL. Plasmapheresis 
was initiated to alleviate his pruritus and reduce the burden 
of circulating bile acids. He underwent 5 sessions of plasma-
pheresis, which was overall well-tolerated but complicated by 
the need for one blood transfusion and a minor skin infection. 
He was discharged on hospital day 20, with total bilirubin 14.4 
mg/dL and creatinine 1.3 mg/dL. Six weeks after discharge he 
was asymptomatic with total bilirubin of 1.2 mg/dL and serum 
creatinine 0.9 mg/dL.
Discussion
Anabolic androgenic steroids (AAS) are considered con-
trolled substances, but are often available online and in 
health and nutrition shops, marketed as dietary supple-
ments. An internet survey of 500 AAS users found that 78% 
were noncompetitive bodybuilders or non-athletes.4 C-17 
alkylated androgenic steroids, which were integral in our pa-
tient’s HDS regimen, are implicated in liver injury resulting in 
prolonged cholestasis.3 We were not able to exclude concur-
rent or synergistic hepatotoxicity from the other ingredients 
in the supplements. Assigning causality in HDS-associated 
hepatotoxicity is difficult; however, given the pattern of bland 
and severe cholestasis on his liver biopsy, we strongly sus-
pected AAS as the offending agent. The underlying mecha-
nism for acute and prolonged cholestasis from AAS remains 
to be elucidated. It is suspected that an unmasking of genet-
ic cholestatic syndromes in predisposed individuals occurs 
through diminished expression of the bile salt export pump 
(encoded by ABCB11).5 
Cholemic nephrosis, also known as bile acid nephropathy, 
is a cholestatic condition presumed to occur from direct bile 
acid-related injury in the form of bile casts, leading to kidney 
tubular cell damage that result in AKI.  Bile acid nephropa-
thy with severe cholestatic liver disease has been described 
in mice with ligated bile ducts and in jaundiced patients 
with AKI.6-8 Elevated plasma concentrations of bile salts and 
bilirubin have been shown to cause nephrotoxicity. Howev-
er, their exact role in the pathogenesis of jaundice-related 
nephropathy is not known. Damage to renal tubular cells 
is considered the cause of the nephropathy, but published 
data on renal histology has been scarce.9 Our patient’s renal 
biopsy showed prominent yellow, brown intraluminal tubular 
casts associated with flattening and simplification of the epi-
thelial lining (Figure 2).
Our patient’s worsening renal function contributed to his 
prolonged jaundice, as bilirubin is filtered and excreted by 
the kidneys. His medical condition resulted in depression, 
Figure 1. Liver biopsy. (A) Intraparenchymal neutrophilic infiltrate consistent with acute hepatitis. Hepatocyte destruction/necrosis is not significant (grade ¼). 
Some scattered chronic inflammatory cells are also present (arrow). (B) No appreciable cirrhosis, overt cytopathic effect or fibrosis.
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inability to work, profound malnutrition, and weight loss. 
Thus, plasmapheresis, which has anecdotal success in pru-
ritus,10 was undertaken with success. Plasmapheresis is an 
extracorporeal therapy that removes toxins, protein-bound 
substances, and even extraneous cells from the body’s 
circulation. Bile acids and toxins can be removed during 
plasmapheresis using specialized beads and resins.11 Plas-
mapheresis has been described in the treatment of pruritus 
from primary biliary cirrhosis,12 benign recurrent intrahepatic 
cholestasis,13 acute hepatitis from Epstein-Barr virus,14 and 
drug-induced liver injury.15 Our patient had a rapid improve-
ment in his cholestatic jaundice, as well as rapid normaliza-
tion of his renal function at the end of his plasmapheresis 
sessions, which were sustained during follow-up. Thus, in 
certain cases of HDS-related liver injury, prolonged persis-
tent cholestasis may lead to persistent kidney injury and pru-
ritus refractory to conventional medical therapy. In selected 
patients with marked decline from prolonged cholestasis, 
plasmapheresis may result in a rapid clinical improvement.
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Figure 2. Renal biopsy showing prominent brown intraluminal casts, tubular epithelial cells (black arrows), and tubular lumen (white arrows). (A) Many of 
the tubules are dilated and show epithelial simplification. (B) Tubule with brown staining of the epithelial lining and of the intraluminal cast. 
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